TY - JOUR T1 - Feasibility and efficacy of a multidisciplinary palliative approach in patients with advanced interstitial lung disease. A pilot randomised controlled trial JO - Pulmonology T2 - AU - Bassi,I. AU - Guerrieri,A. AU - Carpano,M. AU - Gardini,A. AU - Prediletto,I. AU - Polastri,M. AU - Curtis,J. Randall AU - Nava,S. SN - 25310437 M3 - 10.1016/j.pulmoe.2021.11.004 DO - 10.1016/j.pulmoe.2021.11.004 UR - https://journalpulmonology.org/en-feasibility-efficacy-multidisciplinary-palliative-approach-articulo-S2531043721002233 AB - Introduction and ObjectivesInterstitial lung diseases (ILDs) encompass a heterogeneous group of parenchymal lung disorders which have a significant burden on quality of life and exercise. The primary purpose of this randomised pilot trial performed in advanced ILD was to determine the feasibility and efficacy of a multidisciplinary palliative care approach (including physiotherapist, psychologist, pulmonologists, and palliative care doctors) to relieve patients’ symptoms of dyspnoea, depression measured with the Center for Epidemiological Studies-Depression (CES-D) scale and quality-of-life (QoL) at 6 and 12 months. Matherials and MethodsFifty patients with confirmed interstitial lung disease at computed tomography (CT) scan and advanced disease were enrolled at our clinic. Patients were randomised to usual care group vs intervention group; in the intervention group, patients were scheduled to meet a physiotherapist, a psychologist, a palliative care doctor, and a pulmonologist specialized in ILD care. Data on dyspnoea, cough, quality of life and depression were recorded; patients in the intervention group were also tested to assess lower body flexibility and strength. ResultsBoth groups showed a worsening in dyspnoea during the time course of the trial, but the Borg scale was less in the intervention group at 6 and 12 months. A similar trend was observed also for the CES-D scale. No differences were observed for the other scales. ConclusionsA multi-disciplinary palliative care intervention in patients with advanced fibrosing interstitial lung disease is feasible and effective. Trial registrationNCT02929966 on ClinGovTrial. ER -